PROSPECTS FOR DEVELOPMENT OF IMMUNOPROPHYLAXIS UP TO 2020 — 2030


Cite item

Full Text

Abstract

Analytic materials on perspectives of immunization up to 2020—2030 are presented. Middle-term and long-term prognoses are proposed, perspectives of development of distinct aspects of immunization are considered including increase of number of infections controlled in framework of national immunization schedule, routine immunization of middle-aged and elderly persons, keeping of routine mass vaccination during epidemiological welfare, development and implementation of alternative methods of immunization as well as using new technologies of vaccine manufacturing. It was concluded that to 2020—2030 synchronous use of vaccines in national immunization schedules framework will result in elimination of several anthroponoses, decreased incidence of widespread childhood infections down to sporadic cases and significant increase of life-span of patients with chronic diseases.

Full Text

ОЖИДАЕМЫЕ СОБЫТИЯ В РАЗВИТИИ ВАКЦИНОПРОФИЛАКТИКИ ДО 2020 — 2030 ГГ
×

About the authors

B. F Semenov

Mechnikov Research Institute of Vaccines and Sera, Moscow, Russia

V. V Zverev

Mechnikov Research Institute of Vaccines and Sera, Moscow, Russia

R. M Khaitov

Institute of Immunology, Moscow, Russia

References

  1. Биологическая безопасность. М., Медицина, 2006.
  2. Воробьев А.А., Патрикеев Г.Т., Абрамова З.А. Итоги исследований по разработке и испытанию живой пероральной оспенной вакцины. Журн. микробиол. 1978, 4: 12-18.
  3. Данные об инфекционной и паразитарной заболеваемости в РФ. http://www.fcgsen.ru.
  4. Зубкова О.В., Логунов Д.Ю., Карпов А.П. и др. Влияние интегрин-связывающей последовательности (RGD) на прикрепление и интернализацию аденовируса птиц CELO в клетки млекопитающих. Мол. ген. микробиол. вирусол. 2008, 2: 32-36.
  5. Логунов Д.Ю., Народицкий Б.С., Гинцбург А.Л. Молекулярно-биотехнологические защиты от патогенов. Ремедиум. 2007, 3: 20-23.
  6. Медуницин Н.В. Вакцинология, М., Триада-Х, 1999.
  7. Медицинская микробиология, вирусология, иммунология. А.А.Воробьев (ред.). М., Медицинское информационное агентство, 2004.
  8. Наркевич М.И., Тымчаковская И.М. Особенности распространения дифтерии в России на фоне массовой иммунизации детей. Журн. микробиол. 1996, 2: 25-29.
  9. Семенов Б.Ф., Воробьев А.А., Егорова Н.Б. и др. Ожидаемые перспективы вакцинологии до 2020 г. Фундаментальные направления молекулярной медицины. СПб, 2005.
  10. Семенов Б.Ф., Баранов А.А. Вакцинопрофилактика детских инфекций: перспективы, проблемы, решения. В: Вакцинопрофилактика при нарушении здоровья. Б.Ф.Семенов, А.А.Баранов (ред.). М., 2001.
  11. Bambini S., Rappuoli R. The use of genomics in microbial vaccine development. Drug Discov. Today. 2009, 14:252-260.
  12. Billeter M.A., Naim H.Y., Udem S.A. Reverse genetics of measles virus and resulting multivalent recombinant vaccines: applications of recombinant measles viruses. Curr. Top Microbiol. Immunol. 2009, 329: 129-162.
  13. Centers for Disease Control and Prevention (CDC). http://www.cdc.gov/vaccines.
  14. Chumakov K., Ehrenfeld E., Wimmer E. et al. Vaccination against polio should not be stopped. Nature Rev. Microbiol. 2007, 5: 952-958.
  15. Demirjian A., Levy O. Novel vaccines: bridging research, development and production, 2008. Expert Rev. Vac. 2008, 7: 1321-1324.
  16. Dilraj A., Sukhoo R., Cutta F.T. et al.Aerosol and subcutaneous measles vaccine: measles antibody responses 6 years after vaccination. Vaccine. 2007. 25: 4170-4174.
  17. Danzig L. Reverse vaccinilogy — a search of genome-derived meningococcal vaccine. Ibid. 2006, 2: 2-11.
  18. Govaert T.M., Thijs C.T., Masurel N. et al. The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. JAMA. 1994, 272: 1661-1665.
  19. Grgacic E.V., Anderson D.A. Virus-like particls: passport to immune recognition. Methods. 2006, 40: 60-65.
  20. Genomics, proteomics and vaccines. G.Grandi (ed.). West Sussex, John Wiley and Sons, 2004.
  21. Heron M.P., Smith B.L. Deaths: leading causes of 2003. Natl. Viral. Stat. Rep. 2007, 55: 1-92.
  22. Hoeischer M., Gangappa S., Zhong W. et. al. Vaccines against epidemic and pandemic influenza. Expert Opin. Drug. Deliv. 2008, 5: 1139-1157.
  23. Index of WHO’s vaccine and immunozation information pages. http://www.who.int/topica/ vaccines/en.
  24. Jordan Report 20th Anniversary. Accelerated development of vaccines. J. Hilleman (ed.). Washington Natiomal institutes of health, 2002.
  25. Kumer R., Burns E. Age-related decline in immunity: implications for vaccine responsiveness. Expert Rev. Vac. 2008, 7: 467-479.
  26. Kaushik D.K., Sehgal D. Developing antibacterial vaccines in genomics and proteomics era. Scand. J. Immunol. 2008, 67: 544-552.
  27. Leroux-Roeis L., Leroux-Roeis G. Current status and progress of prepandemic and pandemic influenza vaccine development. Exp. Rev. Vac. 2009, 6: 401-423.
  28. Mikszta J.A., Laurent P. Cutaneous delivery of prophylactic and therapeutic vaccines: historical perspective and future out look. Ibid. 2008, 7: 1329-1339.
  29. Mann J.F.S., Acevedo R., Campo J. et. al. Delivery systems: a vaccine strategy for overcoming mucosal tolerance? Ibd. 2009, 8: 103-112.
  30. Malkevitch N., Robert-Guroff N. A call for replicating vector prime-boost strategies in HIV vaccine desing. Expert Rev. Vac. 2004, 4: 105-117.
  31. Moyle P.M., McGeary R.P., Blanchfield J.T. et al. Mucosal immunisation: adjuvants and delivery systems. Curr. Drug. Deliv. 2004, 1: 385-396.
  32. Novel vaccination strategies. S.Kaufmann (ed.). Weinheim, Wile y — VCH verlag GmbH & Co. KgaA, 2004.
  33. Neutra M.R., Kozlowski P.A. Mucosal vaccines: the promise and the challenge. Nature Rev. Immunol. 2006, 6: 148-158.
  34. Nagy G., Emody L., Pal T. Strategies for the development of vaccines conferring broadspectrum protection. Int. J. Med. Microbiol. 2008, 298: 379-395.
  35. Orenstein W.A., Rodewald L.E., Hinman A.R. et al. Immunization in the United States. In: Vaccines. S.Plotkin, W. Orenstein, P. Offit (ed.). Saunders, Elsevier, 2008, p. 1479-1510.
  36. Plotkin S.A. Vaccination in the 21st centure. J. Infect. Dis. 1993, 168: 29-37.
  37. Peek L.J., Middaugh C.R., Berkland C. Nano- technology in vaccine delivery. Adv. Drug Deliv. Rev. 2008, 60: 915-928.
  38. Rybicki E.P. Plant-producud vaccines: promise and reality. Drug Dicov. Today. 2009, 14: 16-24.
  39. Stevceva L., Ferrari M.G. Mucosal adjuvants. Curr. Pharm. Des. 2005, 11: 801-811.
  40. Sykes K. Progress in the development of genetic immunization. Expert Rev. Vac. 2008, 7: 1395-1404.
  41. The GAVI Alliance (formerly global alliance for vaccines and immunisation). http://www.vaccinealliance.org.
  42. Update on vaccine-derived polioviruses — Worldwide, January 2006-August 2007. MMWR, 2007, 56: 996-1001.
  43. Vajdy M., O’Hagan D.T. Microparticles for intranasal immunization. Ad. Drug. Deliv. Rev. 2001, 51: 127-141.
  44. Vivon A.S., Gardy J.L., Ramachandran S et al. Computer-aided biotachnology: from immunoinformatics to reverse vaccinology. Trends Biotechnol. 2006, 26: 190-200.
  45. WHO position papers on specific vaccines. http// www.immunize.org/who.
  46. Wong-Chew R.M., Islas-Romero R., Garcia- Garcia M. et.al. Induction of cellular and humoral immunity after aerosol or subcutane ous administration of Edmonston-Zagreb measles vacine given as a primary dose to 12-month old children. J. Infect. Dis. 2004, 189: 254-257.
  47. Walpita P., Plick. Reverse genetics of negativestranded RNA viruses: a global perspective. FEMS. Microbiol. Lett. 2005, 244: 9-18.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2010 Semenov B.F., Zverev V.V., Khaitov R.M.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ПИ № ФС77-75442 от 01.04.2019 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies